BioSpace News Archive

TAI Diagnostics Announces New Publication using the myTAIHEART® Test in The Journal of Heart and Lung Transplantation

Hoth Therapeutics, Inc. (NASDAQ:HOTH), is one such pharmaceutical company focused on providing eczema patients with a non corticosteriod therapeutic that actually helps treat eczema rather than just stop the itch.

Oral presentation on data from Phase 1b trial in patients with platinum-resistant ovarian cancer

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized research-driven cannabis extraction, distillation and purification, today announced that the Australian Therapeutic Goods Administration (the “TGA”) has notified the Company that its Canadian manufacturing facility meets the requirements for Good Manufacturing Practice for Medicinal Products (“GMP”)

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today updated data from the triple combination arm of the ongoing Phase 2a COMBAT/KEYNOTE-202 study.

Bristol-Myers Squibb Company (NYSE:BMY) announced today that John Elicker, Executive Vice President, Corporate Affairs and Investor Relations, will retire from the company March 31, 2020.

Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF) announces a proposed shares-for-debt transaction in which the Company would issue 192,907 common shares, at a price of CAD $0.41 per share, to an arm’s length third party creditor of the Company in connection with the settlement of an aggregate of USD $60,000 of debt.

FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD Pharma” or the “Company”) announces that Raza Bokhari, MD, Executive Co-Chairman and Chief Executive Officer, will present an overview of the Company at the Investor Summit conference at 2:35 p.m. ET on Tuesday, December 17, 2019 at the Kimpton Hotel Monaco in Philadelphia.

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it has submitted its Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for obeticholic acid (OCA) for the treatment of fibrosis due to nonalcoholic steatohepatitis (NASH).

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced today results from the EMPERIAL-Reduced and EMPERIAL-Preserved trials related to functional endpoints with Jardiance® (empagliflozin) in adults with chronic heart failure with reduced and preserved ejection fraction, respectively.